BRAF and malignant colon neoplasm: Our finding of a higher prevalence of BRAF mutations in right‐sided tumors is consistent with a recent meta‐analysis that reported a significant association between right‐sided colon cancer and BRAF V600E mutation (odds ratio: 4.85; 95% CI: 3.59‐6.56).71 Clinical trials have reported BRAF mutations were not predictive of response to cetuximab72 or panitumumab,73 although the sample sizes were small.